Total Funding
32
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
Biocept employs cell separation technology to develop a class of diagnostic assays for the early detection and diagnosis of cancer.
Lyle Arnold: Senior VP, R&D & CSO- Antonino Morales: President and CEO
About the Company
Biocept, an emerging biotechnology leader in cell separation technology, is developing a new, powerful class of diagnostic assays for personalized medicine in early detection, diagnosis and monitoring of cancer. The CEE™ Cell Enrichment and Extraction platform combines sophisticated attachment chemistry with mathematically modeled fluid dynamics to
enable earlier, accurate, less invasive diagnoses. Isolation, purification and analysis of rare cells are managed within their state-of-the-art CLIA-accredited laboratory. The clinical laboratory is accredited by the College of American Pathologists (CAP) and holds licenses in California and several other states.
